

Femarelle®

Unstoppable

INTENDED USE:

Femarelle® Unstoppable is intended for post-menopausal women for the maintenance of normal bones and better quality of life.

WHY IS FEMARELLE® UNSTOPPABLE RIGHT FOR YOU?

Studies have shown that Femarelle® Unstoppable assists with new bone formation and with vaginal dryness, it assists with energy levels and provides better quality of life to women that want to take care of their bone health. (For full list of published studies please see reverse side)

WHAT IS FEMARELLE® UNSTOPPABLE?

Femarelle® Unstoppable comprises a unique formulation that includes the proprietary fermented soy derivative (DT56a), vitamin B₂, Biotin (vitamin B₇), vitamin D₃ and calcium.

Vitamin D contributes to the maintenance of normal bones and helps to reduce the risk of falling associated with postural instability and muscle weakness. Falling is a risk factor for bone fractures among men and women 60 years of age and older.

In addition, the compounds within contribute to the maintenance of normal mucous membranes, normal skin and the normal functioning of the nervous system, as well as maintain normal hair and normal psychological function.

Femarelle® Unstoppable is produced by employing a unique manufacturing procedure without using any harsh chemicals during the production process. The proprietary soy extract of DT56a uses the whole soy compound. This unique method increases the bio-availability of the active components that are found in Femarelle® Unstoppable.

Femarelle® Unstoppable contains no estrogen and is not an isoflavone isolate.

WHY ARE YOU SUFFERING FROM THESE SYMPTOMS?

Starting from the age of about 30, women experience a gradual process of bone loss that progresses steadily until menopause, the decline in estrogen accelerates the process of bone loss to between 2% and 4% a year. This process leads to low bone mass and structural deterioration of bone tissue, resulting in bone fragility and greater susceptibility to fractures, especially of the hip, spine, and wrist.

In addition, one of the manifold functions of estrogen in the body is to ensure the growth and blood supply

of mucous membranes. The decline in estrogen levels can lead to unpleasant symptoms that are particularly felt in the vagina. The lining of the vagina becomes thinner and drier, becoming red and irritated, itching can occur, and the tissues are more easily injured. This can make intercourse difficult or even impossible. The estrogen deficiency also alters the normal balance of bacteria in the vagina. The healthy acidic environment is replaced by a more alkaline one, and this increase in pH can result in frequent infections of the vagina and bladder.

RECOMMENDED INTAKE:

Femarelle® Unstoppable should be taken twice a day, one capsule in the morning and one in the evening. Swallow the capsule with some water. Femarelle® Unstoppable can be taken with or without food. It is important that you take two capsules a day as this is the required dose for optimal benefit.

If a dose is missed, one capsule should be taken as soon as possible and the regular schedule should then be continued. There is no need to take a double dose to make up for a missed dose.

COMPOSITION:

Each capsule contains:

DT56a- Glycine max (Fermented SOYBEAN extract)	322 mg
Capsule shell (Bovine gelatin- BSE/TSE free)	96 mg
Calcium (as carbonate) (CaCO ₃ 200 mg- equivalent to Ca 80 mg.)	80 mg
Vitamin B ₂ (Riboflavin)	1 mg
D-Biotin	100 µg
Vitamin D ₃ (cholecalciferol)	10 µg (400 I.U.)

CAUTION:

Please note that supplements should not be used as a substitute for a varied diet and healthy lifestyle. As with other supplements, if you have any condition requiring medical attention or are taking prescribed drugs, consult your doctor before taking this product. Not for use during pregnancy, breastfeeding or for children under 12.

Femarelle®

Unstoppable

ADVERSE REACTIONS:

No significant adverse reactions have been reported to date. However, along with its desired effects, any product may have some unwanted effects, these effects were found to be transient and disappeared once the product was discontinued. Your healthcare practitioner should be informed as soon as possible in case you feel unwell while using this product. Any adverse events should also be reported to: pharmacovigilancemt@mint.com.mt

STORAGE:

Store in a cool and dry place (room temperature- do not exceed 30°C). Even if kept in their original container and stored as recommended, health products may be kept for a limited period. Please note that you can't use it beyond the expiry date written on the blister pack. Do not store different medications in the same package. Keep out of reach of children.

MANUFACTURER:

Se-cure Pharmaceuticals Ltd., Dalton Industrial Area, 1381100, Israel

DISTRIBUTOR:

Mint Health Ltd, 3 / 4, Cantrija Complex, Triq it-Targa, Il-Maghtab, Naxxar NXR6613, MALTA

For more information or questions, please visit our website at www.femarelle.mt

References:

1. Yoles I. et al. Efficacy and Safety of Standard versus Low Dose of Femarelle (Tofupill) for the Treatment of Menopausal Symptoms. *J. of Clin Exper Obstet Gynecol* 2004; 31(2):123-26.
2. Labos G., Trakakis E. et al Efficacy and safety of DT56a (Femarelle) compared to hormone therapy in Greek postmenopausal women. *J Endocrinol. Invest.* 2013; 36(7):521-6
3. Genazzani AR et al. Brain region responsiveness to DT56a (Femarelle) administration on allopregnanolone and opioid content in ovariectomized rats. *Menopause* 2009; 16(5):1037-43.
4. Genazzani A., Nachtigall L., Panay N. & Yoles I. Symposium: 2 Continents, 3 cultures, 4 countries, 2,000 women and Femarelle®; *13th World Congress on Menopause*. Rome, Italy June 2011
5. Nachtigall M. et al. A Prospective Study of DT56a (Femarelle) for the Treatment of Postmenopausal Vaginal Atrophy. *Menopause* book of abstract of the NAMS 22nd Annual Meeting, Sept, 2011, p. 55
6. Yoles I. et al. Tofupill/Femarelle (DT56a) - a New Phyto-Selective Estrogen Receptor Modulator-like Substance for the Treatment of Postmenopausal Bone Loss. *Menopause* 2003; 10(6):522-25
7. Somjen D, Yoles I. DT56a (Tofupill/Femarelle), selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus. *J. of Steroid Biochemistry & Molecular Biology* 2003; 86(1):93-98
8. Somjen D. et al. DT56a (Femarelle/Tofupill) Stimulates Bone Formation in Female Rats. *British J. of Obstetrics & Gynecology* 2005; 112(7):981-85.
9. Somjen D., Katzburg S. Lieberherr M., Hendel D., Yoles I. DT56a Stimulates Gender-Specific Human Cultured Bone Cells In Vitro. *J. of Steroid Biochemistry & Molecular Biology* 2006; 98(1):90-96.
10. Somjen D. et al. The Effects of Native and Synthetic Estrogenic Compounds as well as Vitamin D Less-Calcemic Analogs on Adipocytes Content in Rat Bone Marrow. *J Endocrinol Invest.* 2011;34(2):106-10
11. Yoles I., and Lilling G. Pharmacological Doses of the Natural phyto-SERM DT56a (Femarelle) Have no Effect on MCF-7 Breast Cancer Cell-Line. *European J. of Obstetrics & Gynecology & Reproductive Biology* 2006; 130(1):140-141.
12. Nachtigall M et al. The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women. *Menopause* 2011;18(3):285-288
13. Oropeza M.V, Orozco S, Ponce H, Campos M.G. Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract. *Reproductive Toxicology* 2005; 20(2):261-66.
14. Somjen D, Yoles I. DT56a (Femarelle): a Natural Selective Estrogen Receptor Modulator (SERM). *J. of Steroid Biochemistry & Molecular Biology* 2007; 104:252-58.
15. Somjen D. et al. DT56a (Femarelle); contrary to estradiol-17β; is effective in human derived female osteoblasts in hyperglycemic condition. *J Steroid Biochem Mol Biol.* 2011; 123:25-29
16. Sánchez-Borrego R, Mendoza N, Llana P. A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms; *Climacteric.* 2015;18(6):813-6
17. Sánchez-Borrego R et al. Efficacy and safety of a phyto-SERM as an alternative to hormone therapy; *Climacteric.* 2015 Jun;18(3):350-7

In order to view the articles please insert Femarelle when entering pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/>

We invite you to share your experience of Femarelle® Unstoppable. Please send an e-mail to: info@se-curepharma.com or join us on Facebook.

We, at Se-cure Pharmaceuticals Ltd, are constantly investing in bringing you as much information regarding the benefits that Femarelle® Rejuvenate can provide you.

You can follow us on: 